[Clinical Case of Using Inclisiran in a Patient with End-Stage Renal Disease, Before and After Kidney...

Patients with end-stage renal disease (ESRD) have a very high risk of cardiovascular disease (CVD). Addressing lipid metabolism disorders for both primary and secondary prevention of cardiovascular complications (CVC) is a critical priority for this population. However, patients with ESRD or organ transplants are frequently excluded from major randomized trials. The lack of large-scale evidence-based studies on lipid-lowering therapy and the risk of drug-drug interactions limit the use of intensive lipid-lowering treatment in this patient cohort. Furthermore, international consensus documents have not been updated to reflect the latest evidence. Consequently, target low-density lipoprotein cholesterol (LDL-C) levels are often not achieved following coronary complications, even with combination therapy (statins + ezetimibe).This article presents a clinical case of the successful use of inclisiran in a female patient with ESRD and confirmed multifocal atherosclerosis, both prior to and following a planned kidney transplant.